ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DXRX Diaceutics Plc

104.00
0.00 (0.00%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 104.00 103.00 105.00 104.50 104.00 104.00 10,813 08:00:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Testing Laboratories 19.5M 724k 0.0086 120.93 87.85M

Diaceutics PLC Diaceutics PLC -- Financial Calendar Update (1787A)

19/01/2024 7:00am

UK Regulatory


Diaceutics (LSE:DXRX)
Historical Stock Chart


From Jan 2024 to Apr 2024

Click Here for more Diaceutics Charts.

TIDMDXRX

RNS Number : 1787A

Diaceutics PLC

19 January 2024

Diaceutics PLC - Financial Calendar Update

Belfast and London, 19 January 2024 - Diaceutics PLC (AIM: DXRX) , a leading technology and solutions provider to pharma and biotech companies, today announces the following financial calendar events.

   --    January 30, 2024 - Trading Update for the 12 months ended 31 December 2023 
   --    May 21, 2024 - Preliminary results for the full year ended 31 December 2023 
   --    June 24, 2024 - Annual General Meeting of shareholders 

Enquiries:

 
 
  Diaceutics PLC 
Ryan Keeling, Chief Executive Officer  Tel: +44 (0)28 9040 6500 
Nick Roberts, Chief Financial Officer  investorrelations@diaceutics.com 
 
Stifel Nicolaus Europe Limited (Nomad  Tel: +44 (0)20 7710 7600 
 & Broker) 
Ben Maddison 
Nick Harland 
Kate Hanshaw 
 
Alma Strategic Communications          Tel: +44(0)20 3405 0205 
Caroline Forde                         diaceutics@almastrategic.com 
Matthew Young 
Kinvara Verdon 
 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network(R)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBBGDBCGBDGSI

(END) Dow Jones Newswires

January 19, 2024 02:00 ET (07:00 GMT)

1 Year Diaceutics Chart

1 Year Diaceutics Chart

1 Month Diaceutics Chart

1 Month Diaceutics Chart

Your Recent History

Delayed Upgrade Clock